At a glance
Summary
Becton Dickinson closed at $189.52, down 1.3% for the week but still up 14.4% over four weeks and 26.2% over 12 weeks. The stock sits 1.8% below its 52-week high, above both its weekly Trend Line and Sharemaestro Fair Value, while volume fell to 0.7x the 13-week average. Sector and industry context is mixed: BDX is outperforming on medium-term returns, but Medical Instruments & Supplies breadth remains uneven.
- BDX closed at $189.52, only 1.8% below its $193.07 52-week high after a 26.2% 12-week advance.
- The weekly Trend Signal is active for a second week, with price 18.5% above the $159.95 Trend Line and 14.5% above Sharemaestro Fair Value of $165.47.
- Latest volume was 7.0M shares, equal to 0.7x the 13-week average of 10.5M and 0.6x the 52-week average of 11.3M.
- BDX’s four-week and 12-week returns are well ahead of US Healthcare and Medical Instruments & Supplies averages, although the latest week was softer.
- Risk is balanced rather than cleanly bullish, with negative next-week expectancy at 42.02% and 26 downside weeks versus 25 upside weeks across the 52-week window.
Company analysis
The move in context
Price action pauses after a strong August run
Becton Dickinson ended the week of 28 August at $189.52, slipping 1.3% after a strong short-term advance. The pullback does not materially disturb the larger move: BDX is still up 14.4% over four weeks, 26.2% over 12 weeks and 28.0% over 52 weeks. The close sits at 94.8% of its 52-week range, leaving the stock just 1.8% below the $193.07 high and well above the $125.21 low.
The Sharemaestro setup is a balanced read. The weekly Trend Signal is active with a two-week streak, and price is 18.5% above the $159.95 Trend Line. It is also 14.5% above Sharemaestro Fair Value at $165.47, which points to premium demand, but also raises the importance of confirmation if the stock is to hold near the top of its range.
Healthcare context supports the move, but industry breadth is not broad
BDX’s medium-term performance stands out inside Healthcare. The US Healthcare group fell 1.5% on average for the week, gained 6.9% over four weeks and rose 17.0% over 12 weeks. BDX roughly matched the sector’s weekly weakness while beating the group over both four and 12 weeks, ranking 13th of 100 on four-week performance and 21st of 100 over 12 weeks.
The Medical Instruments & Supplies industry is less uniformly supportive. Industry averages show a 0.1% weekly decline, a 4.7% four-week gain and a 12.2% 12-week gain, so BDX is ahead on the longer windows but weaker on the latest week. Breadth is mixed: only 48.0% of industry names have active weekly trend signals and 42.0% show positive relative strength, even though 66.0% have positive activity pressure. BDX is on the stronger side of that split, with active trend, positive Market Dynamics and positive Relative Strength.
Momentum is constructive, volume is the missing ingredient
Market Dynamics remains positive at 1.07, and Relative Strength is positive at 10.53, giving the stock a constructive activity and peer-performance profile. The signal state is not a fresh buy signal, however, and the latest week’s decline interrupts a run of gains that included 5.9%, 6.8%, 3.7% and 4.7% weekly advances from late July through 21 August.
Participation is the main caution. Latest volume was 7.0M shares, below the 13-week average of 10.5M and the 52-week average of 11.3M. That 0.7x volume ratio means the near-high consolidation has not yet drawn strong incremental sponsorship. The best recent confirmation came in late June, when BDX gained 8.3% on 23.6M shares, but the latest price action is taking place on much lighter trading.
Risk and what to watch next
The risk profile is not stretched on volatility alone, with 13-week weekly-return volatility at 3.7% against a 52-week baseline of 3.5%. The distribution is more mixed: BDX has logged 25 upside weeks and 26 downside weeks in the past year, with average positive weeks of 3.4% versus average negative weeks of 2.2%. That helps explain why the stock can show strong medium-term upside while still producing regular pullbacks.
The next test is whether BDX can stay close to the 52-week high while improving participation. A move with volume above 1.5x average would carry more weight than another low-volume push. On the downside, the $159.95 Trend Line remains the key weekly regime level, while fading activity pressure would warn that the rebound is losing support. The negative next-week expectancy reading of 42.02% also argues for watching confirmation rather than assuming immediate continuation.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line65.0%
Positive Relative Strength55.0%
US Medical Instruments & Supplies
50 tracked companiesAbove Trend Line48.0%
Positive Relative Strength42.0%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 2-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- Next-week expectancy is negative at 42.02% based on similar historical setup states.
- 1 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/bdx-26-percent-quarter-low-volume-pause/.
Follow new Sharemaestro research through the RSS feed or JSON feed.